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Abstract 
Background: Low-dose spironolactone has been proven to be effective for resistant hypertension in the general 
population, but this has yet to be confirmed in type 2 diabetic (T2DM) patients. We assessed the efficacy of a low-
dose spironolactone on resistant hypertension in a sub-Saharan African population of T2DM patients from Cameroon.
Methods: This was a four-week single blinded randomized controlled trial in 17 subjects presenting with resist-
ant hypertension in specialized diabetes care units in Cameroon. They were randomly assigned to treatment with a 
daily 25 mg of spironolactone (n = 9) or to an alternative antihypertensive regimen (n = 8), on top of any ongoing 
regimen and prevailing lifestyle prescriptions. They were seen at the start of the treatment, then 2 and 4 weeks later. 
The primary outcome was change in office and self-measured blood pressure (BP) during follow-up, and secondary 
outcomes were changes in serum potassium, sodium, and creatinine levels.
Results: Compared with alternative treatment, low-dose spironolactone was associated with significant decrease in 
office systolic BP (−33 vs. −14 mmHg; p = 0.024), and in diastolic BP (−14 vs. −5 mmHg; p = 0.006). After 1 month of 
spironolactone, all the patients were controlled based on BP below 130/80 mmHg, with significant office BP reduction 
from 158 ± 17/86 ± 11 to 125 ± 11/72 ± 8, vs. 158 ± 8/94 ± 8 to 144 ± 17/89 ± 12 mmHg in the alternative treat-
ment group. There was no significant variation in sodium and creatinine levels in both groups, but a mild increase of 
potassium levels in the spironolactone group.
Interpretation: Add-on low-dose spironolactone was effective in reducing BP to optimal levels in T2DM Cameroo-
nian patients despite mild increase in serum potassium.
Trial registration ClinicalTrials.gov Identifier NCT02426099. Date of registration April 2015
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Background
Hypertension and diabetes have reached epidemic pro-
portions worldwide, fuelling a burden of cardiovascular 
disease. It is estimated that at least 1 billion adults 
have hypertension globally, a figure that is projected 
to increase to 1.5 billion by 2025 [1]. The International 
Diabetes Federation (IDF) has estimated that the num-
ber of adults with diabetes in the world will increase by 
55 %, from 381.8 million in 2013 to 591.9 million in 2035 
[2]. Hypertension is very frequent in diabetes patients. 
It affects up to 70  % of individuals with diabetes and is 
approximately twice more common in individuals with 
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diabetes than in those without [3]. Coexistence of diabe-
tes and hypertension is associated with increased cardio-
vascular morbidity and mortality [4–6].
Blood pressure (BP) control is a huge challenge in dia-
betic patients, especially those of African ancestry. To 
date, there is a general consensus on angiotensin convert-
ing enzyme (ACE) inhibitors as first-line treatment for 
hypertension in diabetic subjects. Diuretics, B blockers 
and calcium channel blockers (CCB) can be added as sec-
ond or third-line treatment to reach the target BP objec-
tives. The choice of these drugs generally takes account 
of existing cofactors or indications [7]. More than 50  % 
of diabetic patients with hypertension do not reach target 
BP control levels, sometimes in spite of double, triple, or 
even quadruple drug therapies [7]. This is partly due to 
resistant hypertension, defined as a failure of appropri-
ate treatment with antihypertensive drugs from three or 
more classes, one of which a diuretic, to lower BP to the 
target level [8].
The prevalence of resistant hypertension is estimated 
at 10–15  % in all patients treated with antihypertensive 
depending on definition and study population [9–12]. It 
is particularly prevalent in diabetes patients. The cause 
of resistant hypertension is in most cases multifacto-
rial, including factors such as poor adherence, obesity, 
vascular stiffening, chronic renal disease as well as an 
underlying endocrine disease like primary aldosteron-
ism; a condition present in 14 % of type 2 diabetes mel-
litus (T2DM) patients with resistant hypertension [13]. 
In addition to its classic effects on sodium-water reten-
tion and excretion of potassium and magnesium, it has 
been proven that aldosterone has cardiovascular effects 
like myocardial fibrosis, cardiac arrhythmia and endothe-
lial dysfunction [14–16]. During the last decade, studies 
like RALES (spironolactone) and EPHESUS (eplerenone) 
have provided reliable evidences on the efficacy of low 
doses of aldosterone antagonists in reducing the morbid-
ity and mortality of severe heart failure and the control of 
resistant hypertension with low doses of spironolactone 
as add-on therapy [17, 18]. However, there is still scarce 
data on the benefit of spironolactone in diabetic patients, 
especially those of African ancestry. To address this clini-
cal issue, we conducted a pilot prospective randomized 
trial to evaluate the effect of low dose spironolactone on 




The study protocol was approved by the National 
Research Ethics Committee for Human Health of Cam-
eroon (Ethical approval N° 077/CNE/SE/2012). Written 
informed consent was obtained from all participants. 
The study was conducted in accordance with the Helsinki 
Declaration.
Protocol and registration
This project was retrospectively registered on Clinical-
Trials.gov in April 2015. NCT02426099. A protocol was 
developed during the planning process.
Design
It was a prospective randomized controlled single 
blinded trial conducted over a six-month period from 
October 2011 to March 2012. There was no change in 
protocol during the study.
Centers and patients
The reference population comprised diabetic patients 
aged  <75  years presenting with a resistant hyperten-
sion of unknown etiology at the outpatient clinics of the 
National Obesity Center and of the Diabetes Care and 
Education Center of the Yaoundé Central Hospital, as 
well as those participating in an ongoing study on gly-
cated hemoglobin (HbA1c). Resistant hypertension was 
defined as an office BP value ≥140/90  mmHg and self-
blood pressure measurement (SBPM)  ≥130/80  mmHg 
under at least three antihypertensive drugs at optimal 
dosages for at least two months, including a diuretic [8]. 
From this population, those who consented were further 
excluded if they fulfilled any of the following criteria: 
T2DM with overt acute/chronic complications, serum 
potassium  ≥5.5  mmol/l, estimated Glomerular Filtra-
tion Rate (eGFR) calculated using the Modification of 
Diet in Renal Disease formula  ≤30  ml/min/1.73  m2 of 
body weight, absolute contraindication to any of the drug 
regimen of the trial, and current aldosterone antagonist 
treatment or cessation within the last 15 months.
Randomization and blinding
The experimental population was divided into two 
groups according to a restricted randomization method 
of blocks [19]. It consisted of drawing without replace-
ment one out of two types of non-distinguishable coun-
ters from a non-transparent bag. Depending on the 
type of counter drawn, the subject was assigned to the 
spironolactone group or to the control group (taking 
an alternative drug regimen) by researchers who were 
aware of the type of counter presented. The alternative 
drug regimen included: candesartan, atenolol and alpha 
methyldopa; and the choice to administer each depended 
on the respective absolute/relative contraindications [20] 
applicable to the subject. As from the randomization day, 
subjects allocated to the spironolactone group received 
a daily 25  mg tablet of spironolactone, whereas those 
from the control group received either a daily 100 mg of 
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atenolol, a daily 8 mg of candesartan, or a daily 750 mg of 
alpha methyldopa, all of these drugs added to their pre-
vious regimen, with unchanged diet. They were followed 
up during visits scheduled at the second and fourth 
weeks of treatment.
Outcomes measures
A clinical examination was done and laboratory meas-
urements carried out before the intervention (baseline) 
and at follow-up visits. Clinical examination included 
BP measurement (at baseline and during all follow-up 
visits), an electrocardiogram (ECG) and anthropomet-
ric parameters recorded at baseline. Biochemical meas-
ures included: serum sodium, serum potassium, serum 
creatinine, fasting capillary glycaemia, the lipid profile 
[including blood cholesterol, triglyceride, high density 
lipoprotein cholesterol (HDL), and low density lipopro-
tein cholesterol (LDL)], blood urea nitrogen (BUN) and 
proteinuria. All biochemical measurements were done 
at baseline and serum sodium, potassium and creatinine 
levels were checked again during visits.
Office BP and self-blood pressure measurement 
(SBPM) were considered at every visit. For office BP, 
three serial measurements taken 5  min apart in the sit-
ting position were obtained from the left arm placed at 
the level of the heart, using an automated sphygmoma-
nometer Omron HEM-705 CP (Omron Corporation, 
Tokyo, Japan). The average of the second and third meas-
urements was used for all analyses. The daytime SBPM 
considered was the mean of BP values self-recorded at 
home in the same condition than those applied in clinic 
three consecutive days prior to the visit, without health 
personnel. ECG was recorded using the CardiMax 
FX-7302 electrocardiograph (Fukuda DenShi, Tokyo, 
Japan). Weight was measured in light clothed subjects 
to the nearest 0.5 kg with a mechanical scale; height was 
measured in the upright position to the nearest 0.5 cm, 
and body mass index (BMI in kg/m2) was calculated as 
weight(cm)/[height(m)x height(m)]. Waist circumference 
was measured at the horizontal plane midway between 
the lower rib margin and the iliac crest with a measuring 
tape. Serum sodium, serum potassium, serum creatinine, 
BUN, serum triglyceride, serum cholesterol and serum 
HDL cholesterol were measured using standard colori-
metric procedures. LDL cholesterol was calculated with 
the Friedwald’s formula [21]. Proteinuria was obtained 
by dipstix of spot urine, and considered positive for at 
least 1+. Fasting glycaemia was recorded using the Accu-
Chek® Compact Plus glucometer (F. Hoffmann-La Roche 
AG, Basel, Switzerland). Unfortunately aldosterone was 
not measured in this study.
All drug information were checked at each visit by 
interviewing the participants and they were invited to 
phone the research team if any change was noticed in-
between visits.
Statistical analysis
We needed at least eight individuals in each group in 
order to detect with 80 % power (ф) and 5 % risk of error 
(α) a minimal relevant difference (δ) of 20 (SD 4) mmHg 
[22] for the systolic blood pressure (SBP) between the 
two groups, considering no dropout, based on the follow-
ing formula [23]:
Data were analyzed based on the intention to treat 
principle, using IBM SPSS for Windows, version 20.0 
(IBM Corp., Armonk New York, USA). Continuous vari-
ables are expressed as means with standard deviation 
(SD), and categorical variables as count (percentage). 
Non parametric Mann–Whitney tests were used to com-
pare continuous variables. A p value  <0.05 was consid-
ered statistically significant.
Results
Out of the 672 diabetic patients received at the enrol-
ment centers between October 2011 and March 2012, 
377 (56.1 %) were hypertensive; of whom 49 (13 %) had a 
diagnosis of resistant hypertension were screened for eli-
gibility. After exclusion of ineligible subjects, 17 patients 
were definitively randomized. None of the participants 
left the trial, and all of them were included in the inten-
tion-to-treat analysis. There was a good compliance to 
treatment and no change in medications occurred during 
the follow up. The trial profile is outlined in Fig. 1.
As expected, the profile of participants was similar 
across the two trial arms at baseline. There were no sex 
differences between the two groups, although this has 
to be interpreted in the context of small numbers. The 
mean office SBP was 158  mmHg in both groups. Mean 
serum potassium, sodium and creatinine levels were 
within normal ranges in both groups. All trial partici-
pants had chronic kidney disease (CKD) according to the 
KDIGO definition as the persistence for at least 3 months 
of an estimated glomerular filtration rate below 60  ml/
min/1.73 m2 [24]. Other characteristics are summarized 
in Table  1. Before the intervention, all trial participants 
were on treatment regimens comprising an ACE inhibi-
tor, a diuretic and a calcium channel blocker. Besides this 
triple therapy, five subjects had a fourth drug, which was 
either alpha or beta-blockers; and the mean daily dosage 
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The mean change in office and self-measured systolic 
and diastolic BP at the end of the trial is presented in 
Table 2. The target BP was defined in this study by sys-
tolic (and diastolic) BP  <130  mmHg (and 80  mmHg) as 
recommended by the IDF up to 2012 [25]. Within the 
spironolactone group, there were significant reductions 
in systolic and diastolic office BP and in systolic SBPM. 
Their mean systolic and diastolic office BP decreased 
respectively from 158 ±  17  mmHg to 125 ±  11  mmHg 
(p  =  0.009) and from 86  ±  11 to 72  ±  8  mmHg 
(p  =  0.009). Only one out of nine participants in the 
spironolactone group did not reach the target office BP 
(with BP = 140/67 mmHg 1 month after); defined by sys-
tolic (and diastolic) BP  <140 (and 90  mmHg). However, 
the target for SBPM, defined by systolic BP (and dias-
tolic) <135 (and 85 mmHg) was reached after 1 month for 
this patient, as all the participants in the spironolactone 
group. Comparing the two groups, the systolic and dias-
tolic BP, both office-based and self-measured, decreased 
more in the spironolactone group than in the control 
group, with the systolic and diastolic office BP respec-
tively decreasing by 33 vs. 14 mmHg (p = 0.024) and by 
14 vs. 5 mmHg (p = 0.006). In the control group, the tar-
get BP was achieved neither for office BP [end-of-trial 
mean BP (mmHg) = 144 ± 17/89 ± 12], nor for SBPM 
[end-of-trial mean BP (mmHg)  =  142  ±  14/86  ±  14]. 
Only two out of eight participants in the control group 
reached the target control BP levels.
Fig. 1 Trial profile
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The mean serum potassium was mildly increased from 
4.02 to 4.38  mmol/L in the spironolactone group after 
4 weeks (Fig. 2), the highest value being at 6.28 mmol/l 
at the end of the trial. But the difference between the 
two study groups was not significant; an observa-
tion made also for serum sodium and creatinine levels 
(Fig.  3). Adverse drug reactions were observed only in 
the spironolactone group at the end of the trial. These 
included: somnolence and asthenia in one patient 
(11.1  %), and hyperkalemia (at 5.61 and 6.28  mmol/l) 
in two other patients (22.2  %) without clinical manifes-
tations. However, these two patients had high initial 
potassium levels of 5.04  mmol/L each. No unexpected 
adverse drug effect was noted.
Discussion
Hypertensive patients with diabetes are at increased 
risk of developing diabetes-specific complications [26]. 
However, achieving and maintaining optimal BP control 
in this population remains a challenge [25, 26]. Unlike 
in the general population where low-dose spironolac-
tone has been shown to be effective for the treatment 
of resistant hypertension [27–29], little is known on 
its efficacy in people with diabetes in whom resistant 
Table 1 Baseline characteristics of the study population
Data are expressed as mean (standard deviations); no statistical difference was found for any of the parameters compared between the spironolactone and control 
groups; Alternative drug regimens include atenolol, candesartan and alpha methyldopa
Current smoking or ceased within the last 3 years
Chronic kidney disease which is the only categorical variable is expressed in number (percentage)
SBP systolic blood pressure; DBP diastolic blood pressure
eGFR estimated glomerular filtration rate using the modification of diet in renal disease equation; HDL-c high density lipoprotein cholesterol; LDL-c low density 
lipoprotein cholesterol
a  Expressed as the average of the second and third measurements
Spironolactone (n = 9) Alternative drug regimen (n = 8) p value
Sociodemographic and clinical characteristics
 Age (years) 64.6 (9.6) 61.0 (6.6) 0.15
 Sex (male/female) 3/6 5/3 0.34
 Smoking 0 0 –
 Alcoholic index (g/l) 0 0 –
 Body mass index (kg/m2) 30.3 (5.4) 30.5 (7.7) 0.95
 Waist circumference (cm) 104.8 (12.5) 102.7 (10.2) 0.74
 Office SBPa (mmHg) 158 (17) 158 (8) 0.96
 Office DBPa (mmHg) 86 (11) 94 (8) 0.08
 Office heart rate (beats/minute) 75 (12) 76 (1) 6 0.92
 Self-measured SBP (mmHg) 140 (9) 151 (15) 0.06
 Self-measured DBP (mmHg) 78 (8) 91 (15) 0.07
Biological parameters
 Fasting glycaemia (g/l) 182.89 (105.45) 141.13 (56.36) 0.33
 Glycatedhaemoglobin (%) 8.45 (1.76) 8.64 (2.43) 0.88
 Blood urea nitrogen (g/l) 0.48 (0.01) 0.48 (0.04) 0.96
 Serum creatinine (mg/l) 15.63 (5.97) 12.45 (3.41) 0.20
 eGFR (ml/min/1.73 m2) 55.25 (23.76) 73.99 (27.96) 0.15
 Serum potassium (mmol/l) 4.02 (0.15) 4.01 (0.10) 0.88
 Serum sodium (mmol/l) 140.5 (0.5) 141.0(0.7) 0.11
 Serum total cholesterol (g/l) 1.71 (0.39) 2.21 (1.00) 0.43
 Serum HDL-C (g/l) 0.58 (0.09) 0.35 (0.10) 0.06
 Serum LDL-C (g/l) 0.88 (0.35) 1.54 (1.20) 0.43
 Serum triglyceride (g/l) 1.32 (0.98) 1.63 (1.43) 0.90
 Proteinuria (number of +) 1.11 (1.6) 1 (1.06) 0.84
Complications
 Chronic kidney disease 9 (100) 8 (100)
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hypertension tends to be highly prevalent and difficult 
to control. This evidence is much needed for patients of 
African ethnicity who have been found to be less respon-
sive to the guidelines recommended first line antihyper-
tensive drugs [ACEI or Angiotensin II Receptor Blocker 
(ARB)] in people with diabetes [25]. Thus, we conducted 
a randomized controlled trial to evaluate the effect of a 
low-dose spironolactone as add-on therapy on office 
and self-measured BP in a group of sub-Saharan Afri-
can T2DM patients with resistant hypertension from 
Cameroon. After 1 month of treatment, a daily 25 mg of 
spironolactone was associated with a significant reduc-
tion of both office and SBPM, and high likelihood of 
reaching recommended target blood pressure, without 
significant change in serum sodium concentrations, and 
only a mild elevation of serum potassium levels.
Table 2 Comparison of blood pressure change after intervention among the two groups and within each group
Data are expressed as means (standard deviations)
SBP systolic blood pressure; DBP diastolic blood pressure
Spironolactone (n = 9) Alternative drug regimen (n = 8) P value
Office blood pressure
 SBP(mmHg)
  Before 158 (17) 158 (8) 0.96
  After 125 (11) 144 (17) 0.02
  p value 0.01 0.08
 DBP(mmHg)
  Before 86 (11) 94 (8) 0.08
  After 72 (8) 89 (12) 0.01
  p value 0.01 0.02
Self-blood pressure measurement
 SBP(mmHg)
  Before 140 (9) 151 (15) 0.06
  After 123 (10) 142 (14) 0.01
  p value 0.02 0.02
 DBP(mmHg)
  Before 78 (8) 91 (15) 0.07
  After 73 (7) 86 (14) 0.04
  p value 0.11 0.09
Fig. 2 Distribution of individual variation of serum sodium and potassium in each group after intervention
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Compared to the alternative drug regimen group, the 
spironolactone group exhibited a significant reduction 
of BP. The achieved reduction in their mean office BP 
(33/14 mmHg) was higher than the 12/7 mmHg reported 
by Hase et al. after treating 25 T2DM Japanese patients 
for 24  weeks with similar dose of spironolactone [30]. 
The more pronounced renal impairment in their popu-
lation could account at least in part to this difference. 
Differing durations of follow-up is also another possi-
ble reason, which would suggest that perhaps, following 
our cohort beyond 4  weeks could reveal some attenu-
ation of the effect of spironolactone with time. It is of 
note however that, in Hase et  al’s study [30], BP reduc-
tion was still significant 2 years after the introduction of 
spironolactone. Oxlund et  al. also reported significant 
reduction in office and ambulatory BP with a fixed daily 
dose of 25  mg of spironolactone in 57 T2DM Danish 
patients after 16  weeks of therapy [31]. These results, 
together with ours, suggest the possible effectiveness of 
small-dose spironolactone in people with diabetes, unlike 
the general population or non-diabetic CKD patients in 
who higher doses are often needed to overcome resistant 
hypertension [29, 32].
Unlike participants in our alternative drug regimen 
group, all those in the spironolactone group reached the 
target office BP of 130/80  mmHg recommended by the 
IDF [25], with the exception one patient who reached 
the target diastolic, but not systolic BP. In the study 
conducted by Oxlund et  al. [31], only 36  % of patients 
receiving spironolactone reached the target BP. Although 
there is continuing debate about the target value of BP 
in T2DM patients, with some claims that the goal of 
130/80  mmHg is less realistic in older populations [26] 
like ours (mean age 64  years), this target is associated 
with a reduced overall and cardiovascular mortality in 
T2DM patients [25], and still seems achievable.
Recent studies in animals and humans, have reported 
that spironolactone produces many other metabolic 
benefits (preventing dyslipidemia) and cardiovascular 
effects in T2DM, beside its known diuretic properties 
[15, 16, 29]. It reduces vascular stiffness and mediates 
vasodilation by increasing nitric oxide bioavailabil-
ity and inhibiting the sympathetic system [33]. These 
last effects are likely more pronounced in resistant 
hypertension, where they translate into reduced pulse-
wave velocity and systolic BP [29, 34]. This can possi-
bly explain the more pronounced action on systolic 
BP observed in our study. Alongside the above effects, 
spironolactone has many other beneficial effects in 
diabetic patients. In particular, it improves endothelial 
function, exerts antithrombogenic effects by blocking 
aldosterone, thereby mediating antithrombotic effects 
[34]. Furthermore, it reduces the risk of inflammatory 
cerebral, myocardial, and renal injury; and is associ-
ated with a reduced prevalence of arrhythmia, heart 
failure, sudden death and post myocardial infarction 
mortality [34]. It has been proven to reduce microal-
buminuria [30]. Considering all these actions, spirono-
lactone should perhaps not be conceived anymore as a 
simple antihypertensive drug, but also as a cardiopro-
tective and nephroprotective drug suitable for diabetic 
patients, in the absence of other contraindications. 
Spironolactone probably has a place among the first-
line antihypertensive drugs in diabetic patients regard-
less of whether they have resistant hypertension or 
not. Indeed, the “aldosterone escape” phenomenon 
characterized by an initial partially reversible decrease 
of aldosterone is well known with the use of ACEI 
Fig. 3 Individual variation of serum creatinine after intervention
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agents, and makes aldosterone specific blockers such 
as spironolactone more effective [34]. Makhlough et al. 
also proved that a low dose spironolactone used alone 
was as effective as spironolactone-losartan combination 
in improving on the diabetic nephropathy [35]. These 
arguments corroborate the fact that it is not an abso-
lute necessity to combine spironolactone which medi-
ates (with better results) all desired effects of ACEI/
ARB with any of those drugs. Such associations are not 
even recommended [25], since they increase the risk 
of adverse drug reactions, including hyperkalemia [27, 
29–32, 35].
Despite the safe dosage of spironolactone used in this 
study, we observed a mild increase in mean serum potas-
sium levels in the spironolactone group. Even though 
severe hyperkalemia was noted in two subjects at the end 
of the study, this was likely driven by their high initial 
level of serum potassium level. Of note, all those patients 
had CKD, which is associated with high risk of hyper-
kalemia [32]. Furthermore, they were all on ACEI which 
can also increase serum potassium levels. The above sug-
gest that caution should be exercised when prescribing 
spironolactone to diabetes patients with serum potas-
sium in the upper end of the normal range, or who have 
concomitant conditions or are receiving treatments that 
can adversely increase potassium levels. Besides hyper-
kalemia, we did observe somnolence and asthenia in one 
patient (11.1 %) in the spironolactone group at the end of 
the trial. These are known mild effects of the drug [36].
Our study is mostly limited by the small sample size, 
limiting our ability to generate stable estimates or to 
perform post hoc subgroups analyses. More adequately 
powered trials with extended follow-up are needed to 
draw definitive conclusions. Indeed, since hypertension 
is a chronic disease, the benefit of low-dose spironolac-
tone in long term treatment of resistant hypertension still 
needs to be demonstrated.
Conclusions
This trial has shown that a low-dose (25 mg) of spirono-
lactone as an add-on therapy for resistant hypertension 
among Black Africans with T2DM was associated with 
a significant reduction of the office and self-measured 
BP to optimal levels after 1 month of treatment, without 
affecting sodium level, but with mild elevation of serum 
potassium.
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